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A B S T R A C T
Bevacizumab is a vascular endothelial growth factor-A-speciﬁc angiogenesis inhibitor indicated as an adjunct to
chemotherapy for the treatment of several types of cancer. Hypertension is commonly observed during bev-
acizumab treatment, and high-grade toxicity can limit therapy and lead to other cardiovascular complications.
The factors that contribute to interindividual variability in blood pressure response to bevacizumab treatment
are not well understood. In this review, we outline research eﬀorts to understand the mechanisms and patho-
physiology of hypertension resulting from bevacizumab treatment. Moreover, we highlight current knowledge of
the pharmacogenetics of bevacizumab-induced hypertension, which may be used to develop strategies to prevent
or minimize this toxicity.
1. Introduction
Bevacizumab (Avastin®, Genentech/Roche) is an angiogenesis in-
hibitor that is approved in the United States for the treatment of pa-
tients with metastatic colorectal cancer, advanced nonsquamous non-
small cell lung cancer, metastatic renal cell carcinoma, recurrent glio-
blastoma, advanced cervical cancer, and platinum-resistant ovarian
cancer (Ferrara & Adamis, 2016). It is also approved for treatment of
metastatic breast cancer in the European Union and other non-U.S.
countries and was approved for this indication in the U.S. between 2008
and 2011. Bevacizumab is typically administered intravenously in the
range of 5–15 mg/kg every 2 or 3 weeks (Genentech, Inc., 2016). The
addition of bevacizumab to standard chemotherapy regimens in the
approved indications has been shown to signiﬁcantly increase overall
survival (OS), progression-free survival (PFS), and/or overall response
rate (Ferrara & Adamis, 2016).
Bevacizumab is a recombinant humanized monoclonal im-
munoglobulin (Ig) G1 antibody that binds to all isoforms and bioactive
proteolytic fragments of human vascular endothelial growth factor-A
(VEGF), which is essential for both normal and tumor angiogenesis. The
antibody contains human framework regions with mutagenized
murine-counterpart residues in six complementarity-determining re-
gions (Ferrara, Hillan, Gerber, & Novotny, 2004). By neutralizing VEGF,
bevacizumab prevents the activation of VEGF tyrosine kinase receptors
VEGFR1 and VEGFR2 on endothelial cells (Fig. 1). The anti-tumor eﬀect
of bevacizumab is primarily attributed to the inhibition of VEGFR2-
mediated angiogenesis (Ferrara et al., 2004), slowing the growth of new
blood vessels and eﬀectively cutting oﬀ a tumor's supply of oxygen and
nutrients. Inhibition of VEGF signaling also improves delivery of cyto-
toxic drugs by lowering tumor interstitial ﬂuid pressure and by redu-
cing the number of non-functional tumor blood vessels.
The most serious adverse eﬀects of bevacizumab are gastrointestinal
perforations, surgery and wound healing complications, and hemor-
rhage (Genentech, Inc., 2016). Other common major adverse drug re-
actions include thromboembolism, proteinuria, and hypertension
(HTN). HTN, a persistent elevation of arterial blood pressure (BP), is
generally asymptomatic, but unmanaged HTN can lead to cardiovas-
cular complications. Rare cases of hypertensive crisis with encephalo-
pathy (Glusker, Recht, & Lane, 2006; Ozcan, Wong, & Hari, 2006) and
subarachnoid hemorrhage (Baizabal-Carvallo, Alonso-Juárez, & Salas,
2010; Dissanayake, Ramakonar, & Lind, 2015; Zand, Kazemi,
Barr, & Afshani, 2012) have also been reported for bevacizumab.
Here, we review the clinical presentation of bevacizumab-induced
HTN and outline proposed mechanisms and biomarkers of this toxicity
that have been discovered through pharmacological and genetic ap-
proaches.
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2. Clinical presentation and management
Bevacizumab-induced HTN is commonly assessed on a scale of 1–5
as deﬁned by the National Cancer Institute's Common Terminology
Criteria for Adverse Events (CTCAE) (National Cancer Institute, 2010),
with grade 3–4 considered as high-grade HTN (Supplementary Table 1).
It should be noted that the deﬁnitions of grades 1–4 hypertension have
changed with each version of the CTCAE, which requires consideration
when comparing incidence rates and biomarker studies from diﬀerent
periods. HTN of all grades has been observed in up to 36% of patients
treated with bevacizumab (Zhu, Wu, Dahut, & Parikh, 2007). The re-
ported incidence of high-grade HTN ranges from 1.8 to 22% (Ranpura,
Pulipati, Chu, Zhu, &Wu, 2010), with up to 1% of events being grade 4
(European Medicines Agency, 2017). In a meta-analysis of twenty phase
II and phase III clinical trials, bevacizumab was reported to increase the
risk of high-grade HTN by up to 5.28-fold (Ranpura et al., 2010). Si-
milar ﬁndings have been reported in other meta-analyses of trials of
breast cancer (Cortes et al., 2012) and colorectal cancer (Loupakis
et al., 2010) and across multiple indications (Zhu et al., 2007).
The time to BP elevation upon receiving bevacizumab varies but is
frequently observed within the ﬁrst cycle of therapy (Maitland et al.,
2010). The toxicity appears to be dose-dependent, with a reported 7.5-
fold increase in all-grade HTN risk in patients treated with high-dose
(≥10 mg/kg) bevacizumab compared to a 3-fold increase in patients
receiving low-dose (< 10 mg/kg) bevacizumab (Zhu et al., 2007). In
the same meta-analysis, the development of grade 3 HTN was observed
in 8.7% of low-dose patients and 16.0% of high-dose patients. Devel-
opment of HTN has also been associated with cumulative dose of bev-
acizumab (Feliu et al., 2015; Mir et al., 2011; Slusarz, Merker,
Muzikansky, Francis, & Plotkin, 2014), while other studies have de-
monstrated no dose eﬀect (Hurwitz et al., 2013). Regardless, high-grade
HTN is still consistently observed at low doses (Hurwitz et al., 2013;
Ranpura et al., 2010; Zhu et al., 2007).
HTN also occurs during treatment with other VEGF pathway in-
hibitors (Maitland et al., 2010), including aﬂibercept, a soluble decoy
receptor that binds VEGF, and small molecule VEGF receptor tyrosine
kinase inhibitors (TKI) such as sunitinib, sorafenib, pazopanib, axitinib,
regorafenib, and cediranib. The frequency of all-grade HTN during
treatment with VEGFR TKIs ranges from 15 to 67%, with a greater
incidence observed during treatment with more potent inhibitors such
as axitinib, regorafenib, and cediranib, where incidence of grade 3–4
HTN has been reported as high as 43% (Brinda, Viganego, Vo,
Dolan, & Fradley, 2016). The correlation of potency and HTN incidence
suggests that HTN is primarily an on-target eﬀect of VEGF inhibition.
Baseline clinical risk factors for VEGF inhibitor-induced HTN have
yet to be established but preexisting HTN has been consistently shown
to correlate directly with the development of treatment-related HTN
(Hamnvik et al., 2015; Isobe et al., 2014; Wicki et al., 2014). Age
(≥60 years) and body mass index (≥25) have also been associated
with anti-VEGF therapy-induced BP elevation (Hamnvik et al., 2015).
Other risk factors may include diabetes mellitus or high fasting glucose
levels, preexisting or family history of cardiovascular disease, dyslipi-
demia, renal disease, subclinical organ damage, and cigarette smoking
(Maitland et al., 2010). Tumor type has also been suggested to have a
role, with the highest risk of bevacizumab-induced HTN being reported
in patients with renal cell carcinoma and breast cancer (An et al., 2010;
Ranpura et al., 2010).
All patients on bevacizumab treatment are recommended to have BP
monitored every two to three weeks. Patients who develop HTN or a
signiﬁcant rise in BP from baseline are recommended to initiate anti-
hypertensive therapy, have current antihypertensive therapy titrated to
better control, or have another agent added (Maitland et al., 2010).
Early initiation of antihypertensive therapy has been shown to reduce
complications, even in life-threatening cases of encephalopathy
(Seet & Rabinstein, 2012), and to prevent or minimize HTN while
continuing bevacizumab treatment (Izzedine et al., 2009; Langenberg
et al., 2009). Bevacizumab is temporarily suspended in patients with
uncontrollable severe HTN and discontinued in the event of hyperten-
sive crisis or hypertensive encephalopathy, with no recommended dose
reductions (Genentech, Inc., 2016). Upon discontinuation of bev-
acizumab, BP typically returns to pre-treatment levels (Maitland et al.,
2010).
Angiotensin-converting enzyme (ACE) inhibitors, angiotensin II re-
ceptor blockers, beta blockers, and calcium channel blockers are all
commonly used to treat angiogenesis inhibitor-induced HTN (Maitland
et al., 2010). No speciﬁc antihypertensive agent provides superior
control of bevacizumab-induced HTN, though diﬀerent classes have
been proposed or recommended against as ﬁrst-line treatment, pri-
marily for other related eﬀects. For example, ACE inhibitors are re-
commended for treatment of proteinuria (also induced by bev-
acizumab) (Dincer & Altundag, 2006), while there is caution against use
of the calcium channel blocker nifedipine, which has been shown to
induce VEGF secretion (Izzedine et al., 2009). Long-acting oral nitrates
have also been reported to successfully restore BP to baseline levels in
patients with HTN refractory to combination treatment with ACE in-
hibitors and calcium channel blockers (Dirix, Maes, & Sweldens, 2007;
Kruzliak, Kovacova, & Pechanova, 2013).
Fig. 1. VEGF signaling and inhibition by bevacizumab.
Vascular endothelial growth factor (VEGF) receptors are
primarily expressed by endothelial cells. VEGFA binds both
VEGFR1 and VEGFR2, although VEGFA-mediated angio-
genesis is primarily through VEGFR2, while VEGFR1 func-
tions primarily as a decoy receptor for VEGFA. Placental
growth factor (PlGF) and VEGFB bind selectively to
VEGFR1, and VEGFC and VEGFD bind to VEGFR3, a key
regulator of lymphangiogenesis. Neuropilin co-receptors
NRP1 and NRP2 also regulate VEGFR signaling. Binding of
VEGF by bevacizumab prevents VEGFA-activated receptor
signaling.
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3. Pathophysiological mechanisms
3.1. Decreased vasodilation
The prevailing hypothesis for the mechanism of bevacizumab-in-
duced HTN is an increase in vascular tone due to inhibition of VEGF-
mediated vasodilation. Direct administration of VEGF has been shown
to induce vasorelaxation and lower BP (Henry et al., 2003, 2001;
Horowitz et al., 1997). Bevacizumab inhibited VEGF-induced vasodi-
lation, measured by outer vessel diameter, in pig retinal arterioles (Su,
Cringle, McAllister, & Yu, 2012), and local administration of bev-
acizumab in human subjects rapidly decreased endothelium-dependent
vasodilation (Thijs et al., 2013). Thus, inhibition of VEGF signaling and
decreased endothelium-dependent vasodilation may result in overall
vascular resistance and the development of HTN.
VEGF signaling through VEGFR2 promotes vascular permeability
and vasodilation (Ferrara, Gerber, & LeCouter, 2003; Li et al., 2002) in
endothelial cells via the downstream release of the vasodilator mole-
cules nitric oxide (NO), produced by endothelial nitric oxide synthase
(eNOS) (Bouloumié, Schini-Kerth, & Busse, 1999; Hood, Meininger,
Ziche, & Granger, 1998), and prostacyclin (Neagoe, Lemieux, & Sirois,
2005; Wheeler-Jones et al., 1997), generated from cyclooxygenase-
catalyzed arachidonic acid metabolism (Fig. 2). NO and prostacyclin act
in a paracrine fashion on adjacent vascular smooth muscle cells to sti-
mulate signaling that ultimately results in vasorelaxation (Robinson,
Khankin, Karumanchi, & Humphreys, 2010). Addition of bevacizumab
to human umbilical vein endothelial cells has been shown to reduce
VEGFR2 phosphorylation (Lee et al., 2007) and decrease NO production
(Wang, Fei, Vanderlaan, & Song, 2004). Administration of an anti-
VEGFR2 antibody in mice resulted in a rapid rise in BP as well as re-
duction of eNOS and neuronal NO synthase expression in the kidney
(Facemire, Nixon, Griﬃths, Hurwitz, & Coﬀman, 2009).
While many studies have shown a decrease in eNOS activity and NO
production during VEGF pathway inhibition, others have shown that
both NO-dependent and NO-independent vasodilation are reduced
(Lankhorst, Kappers, van Esch, Danser, & van den Meiracker, 2014).
Therefore, other endothelial signaling pathways adjacent to VEGF sig-
naling have been proposed contributors to a decrease in vasodilation.
One such pathway focuses on the action of endothelin-1 (ET-1). ET-1
exerts its eﬀects on neighboring vascular endothelial and smooth
muscle cells via activation of ETA and ETB receptors (Vignon-Zellweger,
Heiden, Miyauchi, & Emoto, 2012). In smooth muscle, where both ETA
Fig. 2. Mechanism of VEGF-mediated vasodilation. Activation of VEGF receptor 2 (VEGFR2) induces cell proliferation, migration and survival, and vascular permeability, leading to
angiogenesis. Signaling through phospholipase C (PLC)-γ activates protein kinase C (PKC) by the generation of diacylglycerol (DAG) and increases the concentration of intracellular
calcium (Ca2+) via inositol 1,4,5-triphosphate (IP3). PKC activation, increased Ca2+, and activation of the PI3K-Akt pathway lead to phosphorylation and activation of endothelial nitric
oxide synthase (eNOS) and generation of nitric oxide (NO). PKC also activates the Ras/MEK/ERK pathway, which in turn upregulates cytosolic phospholipase A2 (cPLA2). cPLA2 releases
arachidonic acid (AA) from phospholipids, which is acted on by cyclooxygenases (COX-1/COX-2) to generate prostaglandin H2 (PGH2), which is then converted to prostacyclin (PGI2) by
prostacyclin synthase (PGIS). NO and PGI2 diﬀuse to adjacent smooth muscle cells, where NO activates soluble guanylate cyclase (sGC), leading to cGMP synthesis. PGI2 binds to
prostacyclin receptors (IP), which activate adenylyl cyclase (AC) and increase cAMP synthesis. cGMP and cAMP lead to decreased intracellular Ca2+ concentrations, which induce
vasorelaxation.
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and ETB receptors are expressed, ET-1 acts as a vasoconstrictor, while in
endothelial cells, which express only ETB receptors, ET-1 promotes
vasodilation (Lankhorst, Kappers, van Esch, Danser, & van den
Meiracker, 2013; Liu, Premont, Kontos, Huang, & Rockey, 2003;
Vignon-Zellweger et al., 2012). VEGF has been shown to inﬂuence ET-1
expression, though the relationship is not entirely understood. Plasma
concentrations of ET-1 have been reported to increase following ad-
ministration of the VEGFR TKI sunitinib in patients (Kappers et al.,
2010). Treatment of human microvascular endothelial cells with VEGF
decreased ET-1 production (Star, Giovinazzo, Lamoureux, & Langleben,
2014) but has also been reported to induce ET-1 expression in bovine
aortic endothelial cells and human umbilical vein endothelial cells
(Matsuura, Yamochi, Hirata, Kawashima, & Yokoyama, 1998; Seol,
Oh, & Kim, 2011). Ongoing research is being conducted to elucidate the
role of ET-1 in the onset of HTN during inhibition of VEGF signaling
(Kappers et al., 2010, 2012; Lankhorst et al., 2014).
3.2. Other sources of vascular resistance
While inhibition of VEGF-mediated vasodilation is the dominant
hypothesis for the pathophysiology of bevacizumab-induced HTN, it
has yet to be established as the sole cause of the toxicity. Other me-
chanisms proposed to contribute to bevacizumab-induced HTN include
other sources of endothelial and vascular dysfunction. Microvascular
rarefaction, or the reduction of capillary density, is a consequence of
inhibiting VEGF (Baﬀert et al., 2006; Kamba et al., 2006), which is
required for endothelial cell survival (Gerber et al., 1998; Lee et al.,
2007). Decreased capillary density may lead to increased systemic
vascular resistance and pressure in larger vessels. A rise in BP accom-
panied by a decrease in dermal capillary density has been observed
after six months of bevacizumab treatment (Mourad, des Guetz,
Debbabi, & Levy, 2008). Arterial stiﬀness, possibly resulting from
changes to extracellular matrix or matrix-interacting proteins, can also
contribute to a systemic rise in BP (Safar, Levy, & Struijker-Boudier,
2003). Increased vascular stiﬀness has been observed in patients treated
with sorafenib (Veronese et al., 2006). Oxidative stress and the pro-
duction of abnormal levels of reactive oxygen species may also con-
tribute to the development of HTN, possibly through reactive oxygen
species-mediated apoptosis of endothelial cells (Case,
Ingram, &Haneline, 2008) or excess oxidation of NO (Schulz, Jansen,
Wenzel, Daiber, &Münzel, 2008), decreasing its bioavailability for va-
sodilator tone.
3.3. Renal dysfunction
Alterations in renal function may also contribute to the develop-
ment of bevacizumab-induced HTN. VEGF expression in kidney en-
dothelial cells and podocytes is needed to maintain normal glomerular
structure and ﬁltration (Coultas, Chawengsaksophak, & Rossant, 2005).
Features of thrombotic microangiopathy were observed in bev-
acizumab-treated patients, and local genetic ablation of VEGF in kidney
podocytes has been shown to lead to glomerular injury and elevated BP
in mice (Eremina et al., 2008). Renal changes may be inﬂuenced by
downregulation of NO, which directly aﬀects tubuloglomerular feed-
back, pressure natriuresis, and sodium homeostasis (Zou & Cowley,
1999). Mice treated with a VEGFR2 inhibitor have a reduction of
kidney eNOS and neuronal NOS expression and a shift in the pressure-
natriuresis relationship (Facemire et al., 2009). Similarly, administra-
tion of sunitinib in rats resulted in renal histological abnormalities and
increased arterial pressure, and treatment of cultured human renal
proximal tubular epithelial cells with sunitinib reduced VEGF-induced
eNOS protein expression (Gu et al., 2009). Activation of the renin an-
giotensin system has also been implicated, though experimental and
clinical evidence have mostly disputed this hypothesis (Facemire et al.,
2009; Lankhorst et al., 2013).
3.4. Clues from other forms of hypertension
Bevacizumab-induced HTN is a type of secondary HTN, or HTN
related to a speciﬁc known etiology, though the exact mechanisms by
which bevacizumab causes HTN (Fig. 3) remain unclear. Other common
causes of secondary HTN include obstructive sleep apnea, renal par-
enchymal disease, renal artery stenosis, primary aldosteronism, thyroid
disease, Cushing's syndrome, pheochromocytoma, and coarctation of
the aorta (Rimoldi, Scherrer, &Messerli, 2014). Monogenic syndromes
are also considered as secondary HTN and have been mapped to at least
Fig. 3. Possible pathophysiological mechanisms of bevacizumab-induced hypertension. Vascular endothelial growth factor (VEGF) blockade by bevacizumab and decreased VEGFR2
signaling contributes to systemic vasoconstriction and increased peripheral resistance as a result of endothelial dysfunction and possibly other vascular abnormalities. Inhibition of VEGF
signaling may also alter renal structure and function, leading to inadequate renal sodium excretion and volume overload. Not all listed mechanisms are supported by substantial evidence.
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25 genetic loci (Padmanabhan, Caulﬁeld, & Dominiczak, 2015). Many
of these highly penetrant rare mutations aﬀect renal salt handling or
mineralocorticoid activity, which regulate electrolyte balance and ﬂuid
volume.
Primary HTN is elevated BP of unknown etiology and aﬀects ap-
proximately one billion adults worldwide and accounts for 9.4 million
deaths each year (World Health Organization, 2013). Studies of pri-
mary HTN have collectively accumulated evidence that BP regulation
entails complex and dynamic interactions among multiple tissue and
organ systems. Dysregulation of sodium and ﬂuid balance and vaso-
motor tone have been implicated in the development of primary HTN,
with environmental and genetic factors perturbing multiple physiolo-
gical mechanisms in the heart and blood vessels, kidney, and neu-
roendocrine system that contribute to both functions (Oparil,
Zaman, & Calhoun, 2003). While the mechanisms of drug-induced HTN
may diﬀer from those causing primary HTN, the pathophysiological and
genetic factors contributing to both types may overlap, and any factors
underlying primary HTN may be exacerbated by drug treatment. Thus,
an understanding of primary HTN is necessary to formulate questions
related to bevacizumab-induced HTN.
Family and twin studies estimate BP to be moderately heritable
(30–50%) (Levy et al., 2007; Miall & Oldham, 1963; Snieder et al.,
2000), and HTN is 2.4 times more common in men with two hy-
pertensive parents (Wang et al., 2008), suggesting that BP regulation is
largely inﬂuenced by genetics. Many genome-wide association studies
(GWAS) have identiﬁed common single nucleotide polymorphisms
(SNP) with small eﬀects on BP. A number of early GWAS (Franceschini
et al., 2013; Kato et al., 2011; Kelly et al., 2013; Levy et al., 2009;
Newton-Cheh et al., 2009; The International Consortium for Blood
Pressure Genome-Wide Association Studies, 2011; Wain et al., 2011)
discovered> 60 genetic loci associated with primary HTN, systolic BP,
or diastolic BP, while more recent studies (Ehret et al., 2016; Hoﬀmann
et al., 2017; Liu et al., 2016; Surendran et al., 2016; Warren et al.,
2017) have nearly doubled that count. Despite numerous large-scale
studies, the genetic architecture of primary HTN is still poorly under-
stood. A majority of identiﬁed SNPs are in noncoding regions with
unknown functional eﬀects, and identifying causal variants and me-
chanisms remains a major challenge. All identiﬁed common variants
together still only explain< 5% of the total variance in BP (Munroe,
Barnes, & Caulﬁeld, 2013), leaving much of the genetic contribution to
BP variability unexplained. More recently, studies of primary HTN
using sequencing methods or exome arrays have been performed to
identify rare and low frequency variants contributing to variability in
BP (Ji et al., 2008; Liu et al., 2016; Morrison et al., 2014; Surendran
et al., 2016; Yu et al., 2016). Future sequencing initiatives in sub-
stantially larger sample sizes may uncover even more variants asso-
ciated with primary HTN that may inform additional pathophysiolo-
gical mechanisms contributing to both primary and secondary forms of
the disease.
4. Pharmacogenetics
While there already exists supporting evidence for the mechanism of
bevacizumab-induced HTN, it remains unknown why such great inter-
individual variability in BP elevation exists among patients treated with
bevacizumab. Both environmental and genetic factors may inﬂuence
the risk and severity of bevacizumab toxicity.
4.1. Bevacizumab pharmacokinetics
The pharmacokinetics of bevacizumab are well-described by a
linear two-compartment model (Lu et al., 2008). Bevacizumab elim-
ination relies on proteolytic catabolism throughout the body and is also
regulated by FcRn-receptor-mediated recycling (European Medicines
Agency, 2017). Body weight and gender explain most of the inter-
individual variability in bevacizumab clearance and volume (Lu et al.,
2008), and thus bevacizumab is administered on a mg/kg basis. Serum
albumin, alkaline phosphatase (ALP), serum aspartate aminotransferase
(AST), and tumor burden have also been reported to aﬀect clearance
rates (Kazazi-Hyseni, Beijnen, & Schellens, 2010). None of these factors
are expected to have a signiﬁcant impact on unbound VEGF levels or
eﬃcacy (Lu et al., 2008). Genetic variants aﬀecting the binding aﬃ-
nities of VEGF (Panoilia et al., 2015) or FcRn (Kazazi-Hyseni et al.,
2010) have been suggested to inﬂuence bevacizumab pharmacoki-
netics, but a signiﬁcant correlation has yet to be established.
4.2. Functional variation in VEGF and VEGFR2
Studies of variation in bevacizumab pharmacodynamics also have
not yet yielded any validated markers to predict bevacizumab eﬃcacy
or toxicity. Attempts to identify tumor-derived biomarkers have been
unsuccessful (Schneider et al., 2008). Because bevacizumab targets
host-mediated angiogenesis, predictors of both eﬃcacy and toxicity are
likely to be host factors. In searching for genetic biomarkers of bev-
acizumab-induced HTN, prior studies have primarily focused on
common functional SNPs in VEGFA and KDR, as these genes encode the
most direct targets of bevacizumab, VEGF and VEGFR2. Several VEGFA
polymorphisms located in the promoter and 5′ and 3′ untranslated re-
gions are associated with diﬀerential VEGF expression and serum levels
(Abajo et al., 2010; Awata et al., 2002; Chen et al., 2011; Koukourakis
et al., 2004; Morita et al., 2013; Renner, Kotschan, Hoﬀmann,
Obermayer-Pietsch, & Pilger, 2000; Steﬀensen, Waldstrøm,
Brandslund, & Jakobsen, 2010). Such polymorphisms include rs699947
[minor allele frequency (MAF) 0.49 in the 1000 Genomes Project
(1000G) EUR population], rs833061 (MAF 0.49), rs1570360 (MAF
0.35), rs2010963 (MAF 0.30), and rs3025039 (MAF 0.12). Nonsynon-
ymous functional variants in KDR are also commonly examined in re-
lation to bevacizumab-induced HTN. rs2305948 (V297I, exon 7; MAF
0.08 in 1000G EUR) results in an amino acid change in the third Ig-like
domain of VEGFR2, which is critical for binding of the VEGF ligand
(Fuh, Li, Crowley, Cunningham, &Wells, 1998; Wang et al., 2007).
rs1870377 (Q472H, exon 11; MAF 0.23 in 1000G EUR) aﬀects the ﬁfth
VEGFR2 Ig-like domain, which contains structural features that inhibit
VEGFR2 signaling in the absence of VEGF (Tao, Backer,
Backer, & Terman, 2001). rs34231037 (C482R; MAF 0.03 in 1000G
EUR), which lies 28 bp downstream of rs1870377 in the same domain,
has been associated with baseline serum VEGFR2 levels as well as
changes in serum VEGFR2 levels in response to pazopanib (Maitland
et al., 2015). This mutation has been shown to induce ligand-in-
dependent constitutive VEGFR2 dimerization and activation
(Sarabipour, Ballmer-Hofer, & Hristova, 2016) and to decrease the
ability of VEGFR2 to activate VEGFR1 expression (Jinnin et al., 2008).
Collectively, these data support a role for abnormalities in VEGF and
VEGFR2 function in altered basal VEGF signaling that inﬂuences bev-
acizumab sensitivity and highlight the complexity of mechanisms un-
derlying this drug-induced toxicity phenotype.
4.3. Genetic studies of bevacizumab-induced hypertension
Previous studies of bevacizumab-induced HTN have identiﬁed sig-
niﬁcant associations between VEGFA and KDR SNPs and incidence of
the toxicity (Table 1). Schneider et al. identiﬁed associations between
rs833061 and rs2010963 with incidence of grade 3–4 HTN in the
ECOG-2100 trial of bevacizumab and ﬁrst-line paclitaxel in patients
with metastatic breast cancer (Schneider et al., 2008). Jain et al. per-
formed a meta-analysis of bevacizumab treated patients across six dif-
ferent trials and identiﬁed carriers of rs1870377 as having greater risk
of developing grade 2+ HTN (Jain et al., 2010). Etienne-Grimaldi et al.
genotyped women with locally recurrent or metastatic breast cancer
receiving bevacizumab-containing therapy and found a signiﬁcant as-
sociation between rs2010963 and all-grade HTN (Etienne-Grimaldi
et al., 2011), though with the opposite direction of eﬀect as reported by
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Schneider et al. In bevacizumab-treated patients with metastatic col-
orectal cancer, Morita et al. identiﬁed rs699947 and rs833061 to be
associated with early grade 2+ HTN (during the ﬁrst two months of
treatment) and rs699947and rs3025039 to be associated with grade
2+ HTN during the entire treatment period (Morita et al., 2013); the
direction of eﬀect for rs833061 agreed with that of Schneider et al.
Sibertin-Blanc et al. identiﬁed an association of rs3025039 with in-
cidence of all-grade HTN in metastatic colorectal cancer patients
(Sibertin-Blanc et al., 2015), with a direction of eﬀect that contradicts
that in the Morita et al. study. Finally, Gampenrieder et al. found an
association between rs2010963 and the incidence of bevacizumab-in-
duced HTN in metastatic breast cancer patients (Gampenrieder et al.,
2016), with a direction of eﬀect that agrees with Schneider et al. but not
Etienne-Grimaldi et al.
More recent studies have expanded the set of examined genes be-
yond VEGFA and KDR. Lambrechts et al. tested 236 SNPs in VEGF
pathway and HTN-related genes in a meta-analysis of six trials of
bevacizumab treatment (Lambrechts et al., 2014). No SNP surpassed
the adjusted signiﬁcance threshold, but SNPs in EGLN3, EGF, WNK1,
and KDR had the strongest associations with all-grade HTN. Schneider
et al. expanded their initial study to a GWAS of bevacizumab-treated
breast cancer patients in ECOG-5103. Intronic SV2C SNP rs6453204
associated with high systolic BP in the discovery study and was vali-
dated for association with grade 3–4 HTN in a subset of ECOG-2100
patients (Schneider et al., 2014). SV2C encodes a synaptic vesicle gly-
coprotein, and Schneider et al. postulate that the protein may inﬂuence
BP through the release of catecholamines from adrenal chromaﬃn cells
and production of aldosterone through adrenocortical connections with
the adrenal medulla. rs1129660, a polymorphism in the autophagy-
related gene FIP200, associated with lower rate of grade 2–3 HTN in
metastatic colorectal cancer patients (Berger et al., 2017). The relation
between FIP200 and HTN is unclear, but Berger et al. suggest that
FIP200 genetic variants may inﬂuence vascular integrity.
Genetic associations with HTN toxicity have also been reported
during treatment with VEGFR TKIs. SNPs in VEGFA, KDR, and NOS3
(eNOS) are associated with sunitinib-induced HTN (Eechoute et al.,
2012; Garcia-Donas et al., 2011; Kim et al., 2012; van Erp et al., 2009).
Variants in genes encoding hepatic and renal drug metabolizing en-
zymes and transporters also associate with TKI toxicities (Diekstra,
Swen, Gelderblom, & Guchelaar, 2016; Semeniuk-Wojtaś, Lubas, Stec,
Szczylik, & Niemczyk, 2016), though these are not expected to aﬀect
bevacizumab pharmacokinetics.
In summary, SNPs in VEGFA, KDR, SV2C, and FIP200 have been
signiﬁcantly associated with incidence of bevacizumab-induced HTN,
and SNPs in EGLN3, EGF, and WNK1 have been modestly associated
with the toxicity. However, the directions of eﬀect for several of these
ﬁndings are discordant, and no association has been replicated con-
sistently across multiple studies or validated with mechanistic studies.
Earlier CTCAE HTN grade 3 criteria had lower thresholds and relied
primarily on subjective interpretation, which may result in diﬀering
case deﬁnitions and spurious associations in studies using CTCAE
grades as the phenotype. Given the complexity of primary HTN, the
genetic architecture contributing to bevacizumab-induced HTN is also
likely to be polygenic. Therefore, further pharmacogenetic research,
ideally with a more quantitative, standardized phenotype, is warranted
in additional cohorts to extend these current ﬁndings. A meta-analysis
across multiple studies is likely needed to overcome sample size lim-
itations inherent in most clinical study populations. Aggregate eﬀects
and interactions of all clinical risk factors and reported risk variants on
bevacizumab-induced HTN should also be examined in larger popula-
tions. Finally, functional studies are necessary to provide evidence for
the involvement of any associated variants in the mechanism of bev-
acizumab-induced HTN.
5. Hypertension as a marker of bevacizumab eﬃcacy
Clinical, radiological, and molecular markers have been examined
to identify biomarkers or other surrogate markers to predict bev-
acizumab eﬃcacy. Genetic markers, most of which consist of the
VEGFA functional polymorphisms mentioned above, have been sig-
niﬁcantly associated with improved OS and PFS in several studies (de
Haas et al., 2014; Eng et al., 2012; Jain et al., 2009; Lambrechts, Lenz,
de Haas, Carmeliet, & Scherer, 2013). However, few of these pharma-
cogenetic ﬁndings have had consistent results.
The relationship between bevacizumab-induced HTN and eﬃcacy
has also been examined, with the development of HTN being proposed
as a pharmacodynamic marker for the inhibition of the VEGF signaling
pathway (Maitland et al., 2006). Multiple studies and meta-analyses
have identiﬁed associations between bevacizumab-induced HTN and
longer OS, PFS, or response rate (Cai et al., 2013; Chen, Sun, Ye,
Weng, & Dai, 2014; Jubb &Harris, 2010; Mangoni, Woodman,
Kichenadasse, Rowland, & Sorich, 2016). The onset of bevacizumab-
induced HTN with superior outcome was rigorously analyzed in a study
of bevacizumab in combination with carboplatin and paclitaxel for the
treatment of advanced non–small-cell lung cancer (ECOG 4599)
(Dahlberg, Sandler, Brahmer, Schiller, & Johnson, 2010). By im-
plementing landmark analyses and adjusting for HTN as a time-varying
covariate, the study demonstrated signiﬁcantly improved OS and PFS in
bevacizumab-treated patients with high BP compared to patients
without high BP; this diﬀerence in outcome by BP status was non-
Table 1
Genetic variants associated with bevacizumab-induced hypertension.
Gene SNP Function Allele change MAFa Hypertension phenotype Minor allele risk eﬀect Reference
VEGFA rs699947 Promoter A > C 0.49 Early grade 2+ Decreased Morita et al. (2013)
Grade 2+ Decreased Morita et al. (2013)
VEGFA rs833061 Promoter C > T 0.49 Grade 3+ Decreased Schneider et al. (2008)
Early grade 2+ Decreased Morita et al. (2013)
VEGFA rs2010963 5′ UTR G > C 0.30 Grade 3+ Decreased Schneider et al. (2008)
All-grade Increased Etienne-Grimaldi et al. (2011)
Grade 3+ Decreased Gampenrieder et al. (2016)
VEGFA rs3025039 3′ UTR C > T 0.12 Grade 2+ Increased Morita et al. (2013)
All-grade Decreased Sibertin-Blanc et al. (2015)
KDR rs1870377 Missense T > A 0.23 Grade 2+ Increased Jain et al. (2010)
KDR rs2305949 Intronic C > T 0.18 All-grade Decreased Lambrechts et al. (2014)
EGLN3 rs1680695 Intronic T > G 0.36 All-grade Increased Lambrechts et al. (2014)
EGF rs4444903 5′ UTR A > G 0.40 All-grade Increased Lambrechts et al. (2014)
WNK1 rs11064560 Intronic T > G 0.30 All-grade Increased Lambrechts et al. (2014)
SV2C rs6453204 Intronic G > A 0.08 SBP > 160 mmHg Increased Schneider et al. (2014)
FIP200 rs1129660 Synonymous A > G 0.21 Grade 2+ Decreased Berger et al. (2017)
a Minor allele frequency reported in 1000 Genomes Project EUR population.
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existent in patients who did not receive bevacizumab. However, other
meta-analyses have found no consistent correlation between HTN and
clinical beneﬁt. In an analysis of seven phase III studies across multiple
tumor types, Hurwitz et al. detected no association between early BP
increase and PFS or OS (Hurwitz et al., 2013). Similarly, Ranpura et al.
found no signiﬁcant correlation between the relative risks of high-grade
HTN and the hazard ratios of PFS or OS in 20 studies of bevacizumab
treatment (Ranpura et al., 2010).
If the development of HTN is indeed predictive of improved clinical
outcomes, cases of high-grade HTN that would normally prompt dis-
continuation of bevacizumab treatment may instead warrant more ag-
gressive treatment of HTN. Dose titration of bevacizumab while closely
monitoring BP has been proposed to improve outcomes (Dewdney,
Cunningham, Barbachano, & Chau, 2012). Because bevacizumab-in-
duced HTN is hypothesized to be an on-target drug eﬀect, identiﬁcation
of genetic variants that inﬂuence both BP regulation and VEGF in-
hibition may enable prediction of both toxicity and eﬃcacy prior to
treatment.
6. Conclusion
HTN is commonly observed during bevacizumab treatment, and
high-grade toxicity can limit therapy and lead to other cardiovascular
complications. While many molecular mechanisms have been proposed
to explain this adverse drug reaction, the factors that contribute to in-
terindividual variability in BP response to bevacizumab treatment are
still not well understood. Pharmacogenetic studies have identiﬁed
variants associated with bevacizumab-induced HTN, and these variants
require further replication and functional validation to establish their
role in the toxicity of bevacizumab-based therapy. Additional research
on the risk factors and mechanisms of bevacizumab-induced HTN is
necessary to support the development of improved and novel strategies
to treat bevacizumab-induced HTN and to minimize the number of
patients impacted by this dose-limiting toxicity.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.pharmthera.2017.08.012.
Conﬂict of interest statement
The authors declare that there are no conﬂicts of interest.
Acknowledgements
Research by the authors on bevacizumab-induced hypertension is
supported by Genentech through the Alliance Clinical Trial Foundation
and the Pharmacogenomics Development Fund to NIH award number
P30CA082103. ML was supported in part by NIH grants T32GM007175
and F31GM113350.
References
Abajo, A., Rodriguez, J., Bitarte, N., Zarate, R., Boni, V., Ponz, M., et al. (2010). Dose-
ﬁnding study and pharmacogenomic analysis of ﬁxed-rate infusion of gemcitabine,
irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients.
British Journal of Cancer, 103, 1529–1535.
An, M. M., Zou, Z., Shen, H., Liu, P., Chen, M. L., Cao, Y. B., & Jiang, Y. Y. (2010).
Incidence and risk of signiﬁcantly raised blood pressure in cancer patients treated
with bevacizumab: An updated meta-analysis. European Journal of Clinical
Pharmacology, 66, 813–821.
Awata, T., Inoue, K., Kurihara, S., Ohkubo, T., Watanabe, M., Inukai, K., et al. (2002). A
common polymorphism in the 5′-untranslated region of the VEGF gene is associated
with diabetic retinopathy in type 2 diabetes. Diabetes, 51, 1635–1639.
Baﬀert, F., Le, T., Sennino, B., Thurston, G., Kuo, C. J., Hu-Lowe, D., & McDonald, D. M.
(2006). Cellular changes in normal blood capillaries undergoing regression after in-
hibition of VEGF signaling. American Journal of Physiology: Heart and Circulatory
Physiology, 290, H547–H559.
Baizabal-Carvallo, J. F., Alonso-Juárez, M., & Salas, I. (2010). Pretruncal subarachnoid
hemorrhage and high cerebral blood ﬂow velocities with bevacizumab therapy.
Clinical Neuropharmacology, 33, 268–269.
Berger, M. D., Yamauchi, S., Cao, S., Hanna, D. L., Sunakawa, Y., Schirripa, M., et al.
(2017). Autophagy-related polymorphisms predict hypertension in patients with
metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from
TRIBE and FIRE-3 trials. European Journal of Cancer, 77, 13–20.
Bouloumié, A., Schini-Kerth, V. B., & Busse, R. (1999). Vascular endothelial growth factor
up-regulates nitric oxide synthase expression in endothelial cells. Cardiovascular
Research, 41, 773–780.
Brinda, B. J., Viganego, F., Vo, T., Dolan, D., & Fradley, M. G. (2016). Anti-VEGF-induced
hypertension: A review of pathophysiology and treatment options. Current Treatment
Options in Cardiovascular Medicine, 18, 33.
Cai, J., Ma, H., Huang, F., Zhu, D., Bi, J., Ke, Y., & Zhang, T. (2013). Correlation of
bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer
patients treated with bevacizumab: A systematic review and meta-analysis. World
Journal of Surgical Oncology, 11, 306.
Case, J., Ingram, D. A., & Haneline, L. S. (2008). Oxidative stress impairs endothelial
progenitor cell function. Antioxidants & Redox Signaling, 10, 1895–1907.
Chen, C., Sun, P., Ye, S., Weng, H. W., & Dai, Q. S. (2014). Hypertension as a predictive
biomarker for eﬃcacy of bevacizumab treatment in metastatic colorectal cancer: A
meta-analysis. Journal of Balkan Union of Oncology, 19, 917–924.
Chen, M. H., Tzeng, C.-H., Chen, P.-M., Lin, J.-K., Lin, T.-C., Chen, W.-S., et al. (2011).
VEGF −460T→ C polymorphism and its association with VEGF expression and
outcome to FOLFOX-4 treatment in patients with colorectal carcinoma. The
Pharmacogenomics Journal, 11, 227–236.
Cortes, J., Calvo, V., Ramírez-Merino, N., O'Shaughnessy, J., Brufsky, A., Robert, N., et al.
(2012). Adverse events risk associated with bevacizumab addition to breast cancer
chemotherapy: A meta-analysis. Annals of Oncology, 23, 1130–1137.
Coultas, L., Chawengsaksophak, K., & Rossant, J. (2005). Endothelial cells and VEGF in
vascular development. Nature, 438, 937–945.
Dahlberg, S. E., Sandler, A. B., Brahmer, J. R., Schiller, J. H., & Johnson, D. H. (2010).
Clinical course of advanced non-small-cell lung cancer patients experiencing hy-
pertension during treatment with bevacizumab in combination with carboplatin and
paclitaxel on ECOG 4599. Journal of Clinical Oncology, 28, 949–954.
de Haas, S., Delmar, P., Bansal, A. T., Moisse, M., Miles, D. W., Leighl, N., et al. (2014).
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing
the addition of bevacizumab to standard therapy. Angiogenesis, 17, 909–920.
Dewdney, A., Cunningham, D., Barbachano, Y., & Chau, I. (2012). Correlation of bev-
acizumab-induced hypertension and outcome in the BOXER study, a phase II study of
capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in
45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront
resection. British Journal of Cancer, 106, 1718–1721.
Diekstra, M. H. M., Swen, J. J., Gelderblom, H., & Guchelaar, H.-J. (2016). A decade of
pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell
cancer: A systematic review. Expert Review of Molecular Diagnostics, 16, 605–618.
Dincer, M., & Altundag, K. (2006). Angiotensin-converting enzyme inhibitors for bev-
acizumab-induced hypertension. Annals of Pharmacotherapy, 40, 2278–2279.
Dirix, L. Y., Maes, H., & Sweldens, C. (2007). Treatment of arterial hypertension (AHT)
associated with angiogenesis inhibitors. Annals of Oncology, 18, 1121–1122.
Dissanayake, A. S., Ramakonar, H. H., & Lind, C. R. P. (2015). Diﬀuse, non-traumatic,
non-aneurysmal subarachnoid haemorrhage during bevacizumab treatment of high
grade glioma: Case report and review of the literature. Interdisciplinary Neurosurgery:
Advanced Techniques and Case Management, 2, 65–68.
Eechoute, K., van der Veldt, A. A. M., Oosting, S., Kappers, M. H. W., Wessels, J. A. M.,
Gelderblom, H., et al. (2012). Polymorphisms in endothelial nitric oxide synthase
(eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced
hypertension. Clinical Pharmacology & Therapeutics, 92, 503–510.
Ehret, G. B., Ferreira, T., Chasman, D. I., Jackson, A. U., Schmidt, E. M., Johnson, T., et al.
(2016). The genetics of blood pressure regulation and its target organs from asso-
ciation studies in 342,415 individuals. Nature Genetics, 48, 1171–1184.
Eng, L., Azad, A. K., Habbous, S., Pang, V., Xu, W., Maitland-van der Zee, A. H., et al.
(2012). Vascular endothelial growth factor pathway polymorphisms as prognostic
and pharmacogenetic factors in cancer: A systematic review and meta-analysis.
Clinical Cancer Research, 18, 4526–4537.
Eremina, V., Jeﬀerson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J., et al.
(2008). VEGF inhibition and renal thrombotic microangiopathy. The New England
Journal of Medicine, 358, 1129–1136.
Etienne-Grimaldi, M. C., Formento, P., Degeorges, A., Pierga, J. Y., Delva, R., Pivot, X.,
et al. (2011). Prospective analysis of the impact of VEGF-A gene polymorphisms on
the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer
patients. British Journal of Clinical Pharmacology, 71, 921–928.
European Medicines Agency (2017). Avastin: EPAR — product information. Retrieved
from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_
Information/human/000582/WC500029271.pdf.
Facemire, C. S., Nixon, A. B., Griﬃths, R., Hurwitz, H., & Coﬀman, T. M. (2009). Vascular
endothelial growth factor receptor 2 controls blood pressure by regulating nitric
oxide synthase expression. Hypertension, 54, 652–658.
Feliu, J., Salud, A., Safont, M. J., García-Girón, C., Aparicio, J., Losa, F., et al. (2015).
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-
treated patients with metastatic colorectal cancer. PloS One, 10, e0116527.
Ferrara, N., & Adamis, A. P. (2016). Ten years of anti-vascular endothelial growth factor
therapy. Nature Reviews Drug Discovery, 15, 385–403.
Ferrara, N., Gerber, H. P., & LeCouter, J. (2003). The biology of VEGF and its receptors.
Nature Medicine, 9, 669–676.
Ferrara, N., Hillan, K. J., Gerber, H. P., & Novotny, W. (2004). Discovery and develop-
ment of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug
Discovery, 3, 391–400.
Franceschini, N., Fox, E., Zhang, Z., Edwards, T. L., Nalls, M. A., Sung, Y. J., et al. (2013).
Genome-wide association analysis of blood-pressure traits in African-ancestry
M. Li, D.L. Kroetz Pharmacology and Therapeutics 182 (2018) 152–160
158
individuals reveals common associated genes in African and non-African populations.
The American Journal of Human Genetics, 93, 545–554.
Fuh, G., Li, B., Crowley, C., Cunningham, B., & Wells, J. A. (1998). Requirements for
binding and signaling of the kinase domain receptor for vascular endothelial growth
factor. Journal of Biological Chemistry, 273, 11197–11204.
Gampenrieder, S. P., Hufnagl, C., Brechelmacher, S., Huemer, F., Hackl, H., Rinnerthaler,
G., et al. (2016). Endothelin-1 genetic polymorphism as predictive marker for bev-
acizumab in metastatic breast cancer. The Pharmacogenomics Journal. http://dx.doi.
org/10.1038/tpj.2016.25 (Advance online publication).
Garcia-Donas, J., Esteban, E., Leandro-García, L. J., Castellano, D. E., del Alba, A. G.,
Climent, M. A., et al. (2011). Single nucleotide polymorphism associations with re-
sponse and toxic eﬀects in patients with advanced renal-cell carcinoma treated with
ﬁrst-line sunitinib: A multicentre, observational, prospective study. The Lancet
Oncology, 12, 1143–1150.
Genentech, Inc. (2016). Avastin prescribing information. Retrieved from https://www.
gene.com/download/pdf/avastin_prescribing.pdf.
Gerber, H. P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., & Ferrara, N.
(1998). Vascular endothelial growth factor regulates endothelial cell survival through
the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: Requirement for
Flk-1/KDR activation. Journal of Biological Chemistry, 273, 30336–30343.
Glusker, P., Recht, L., & Lane, B. (2006). Reversible posterior leukoencephalopathy
syndrome and bevacizumab. The New England Journal of Medicine, 354, 980–982.
Gu, J.-W., Manning, R. D., Young, E., Shparago, M., Sartin, B., & Bailey, A. P. (2009).
Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced
hypertension in Sprague-Dawley rats. American Journal of Physiology. Regulatory,
Integrative and Comparative Physiology, 297, R142–8.
Hamnvik, O. P., Choueiri, T. K., Turchin, A., McKay, R. R., Goyal, L., Davis, M., et al.
(2015). Clinical risk factors for the development of hypertension in patients treated
with inhibitors of the VEGF signaling pathway. Cancer, 121, 311–319.
Henry, T. D., Annex, B. H., McKendall, G. R., Azrin, M. A., Lopez, J. J., Giordano, F. J.,
et al. (2003). The VIVA trial: Vascular endothelial growth factor in ischemia for
vascular angiogenesis. Circulation, 107, 1359–1365.
Henry, T. D., Rocha-Singh, K., Isner, J. M., Kereiakes, D. J., Giordano, F. J., Simons, M.,
et al. (2001). Intracoronary administration of recombinant human vascular en-
dothelial growth factor to patients with coronary artery disease. American Heart
Journal, 142, 872–880.
Hoﬀmann, T. J., Ehret, G. B., Nandakumar, P., Ranatunga, D., Schaefer, C., Kwok, P.-Y.,
et al. (2017). Genome-wide association analyses using electronic health records
identify new loci inﬂuencing blood pressure variation. Nature Genetics, 49, 54–64.
Hood, J. D., Meininger, C. J., Ziche, M., & Granger, H. J. (1998). VEGF upregulates ecNOS
message, protein, and NO production in human endothelial cells. American Journal of
Physiology: Heart and Circulatory Physiology, 274, H1054–H1058.
Horowitz, J. R., Rivard, A., van der Zee, R., Hariawala, M., Sheriﬀ, D. D., Esakof, D. D.,
et al. (1997). Vascular endothelial growth factor/vascular permeability factor pro-
duces nitric oxide-dependent hypotension. Evidence for a maintenance role in
quiescent adult endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, 17,
2793–2800.
Hurwitz, H. I., Douglas, P. S., Middleton, J. P., Sledge, G. W., Johnson, D. H., Reardon, D.
A., et al. (2013). Analysis of early hypertension and clinical outcome with bev-
acizumab: Results from seven phase III studies. The Oncologist, 18, 273–280.
Isobe, T., Uchino, K., Makiyama, C., Ariyama, H., Arita, S., Tamura, S., et al. (2014).
Analysis of adverse events of bevacizumab-containing systemic chemotherapy for
metastatic colorectal cancer in Japan. Anticancer Research, 34, 2035–2040.
Izzedine, H., Ederhy, S., Goldwasser, F., Soria, J. C., Milano, G., Cohen, A., et al. (2009).
Management of hypertension in angiogenesis inhibitor-treated patients. Annals of
Oncology, 20, 807–815.
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeﬄer, J. S., et al.
(2009). Biomarkers of response and resistance to antiangiogenic therapy. Nature
Reviews Clinical Oncology, 6, 327–338.
Jain, L., Sissung, T. M., Danesi, R., Kohn, E. C., Dahut, W. L., Kummar, S., et al. (2010).
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and im-
proved clinical outcome following bevacizumab and sorafenib. Journal of
Experimental & Clinical Cancer Research, 29, 95.
Ji, W., Foo, J. N., O'Roak, B. J., Zhao, H., Larson, M. G., Simon, D. B., et al. (2008). Rare
independent mutations in renal salt handling genes contribute to blood pressure
variation. Nature Genetics, 40, 592–599.
Jinnin, M., Medici, D., Park, L., Limaye, N., Liu, Y., Boscolo, E., et al. (2008). Suppressed
NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile
hemangioma. Nature Medicine, 14, 1236–1246.
Jubb, A. M., & Harris, A. L. (2010). Biomarkers to predict the clinical eﬃcacy of bev-
acizumab in cancer. The Lancet Oncology, 11, 1172–1183.
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., et al.
(2006). VEGF-dependent plasticity of fenestrated capillaries in the normal adult
microvasculature. American Journal of Physiology: Heart and Circulatory Physiology,
290, H560–76.
Kappers, M. H. W., de Beer, V. J., Zhou, Z., Danser, A. H. J., Sleijfer, S., Duncker, D. J.,
et al. (2012). Sunitinib-induced systemic vasoconstriction in swine is endothelin
mediated and does not involve nitric oxide or oxidative stress. Hypertension, 59,
151–157.
Kappers, M. H. W., van Esch, J. H. M., Sluiter, W., Sleijfer, S., Danser, A. H. J., & van den
Meiracker, A. H. (2010). Hypertension induced by the tyrosine kinase inhibitor su-
nitinib is associated with increased circulating endothelin-1 levels. Hypertension, 56,
675–681.
Kato, N., Takeuchi, F., Tabara, Y., Kelly, T. N., Go, M. J., Sim, X., et al. (2011). Meta-
analysis of genome-wide association studies identiﬁes common variants associated
with blood pressure variation in east Asians. Nature Genetics, 43, 531–538.
Kazazi-Hyseni, F., Beijnen, J. H., & Schellens, J. H. M. (2010). Bevacizumab. The
Oncologist, 15, 819–825.
Kelly, T. N., Takeuchi, F., Tabara, Y., Edwards, T. L., Kim, Y. J., Chen, P., et al. (2013).
Genome-wide association study meta-analysis reveals transethnic replication of mean
arterial and pulse pressure loci. Hypertension, 62, 853–859.
Kim, J. J., Vaziri, S. A. J., Rini, B. I., Elson, P., Garcia, J. A., Wirka, R., et al. (2012).
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hyperten-
sion and clinical outcome in metastatic clear cell renal cell carcinoma patients treated
with sunitinib. Cancer, 118, 1946–1954.
Koukourakis, M. I., Papazoglou, D., Giatromanolaki, A., Bougioukas, G., Maltezos, E., &
Siviridis, E. (2004). VEGF gene sequence variation deﬁnes VEGF gene expression
status and angiogenic activity in non-small cell lung cancer. Lung Cancer, 46,
293–298.
Kruzliak, P., Kovacova, G., & Pechanova, O. (2013). Therapeutic potential of nitric oxide
donors in the prevention and treatment of angiogenesis-inhibitor-induced hyperten-
sion. Angiogenesis, 16, 289–295.
Lambrechts, D., Lenz, H.-J., de Haas, S., Carmeliet, P., & Scherer, S. J. (2013). Markers of
response for the antiangiogenic agent bevacizumab. Journal of Clinical Oncology, 31,
1219–1230.
Lambrechts, D., Moisse, M., Delmar, P., Miles, D. W., Leighl, N., Escudier, B., et al. (2014).
Genetic markers of bevacizumab-induced hypertension. Angiogenesis, 17, 685–694.
Langenberg, M. H. G., van Herpen, C. M. L., De Bono, J., Schellens, J. H. M., Unger, C.,
Hoekman, K., et al. (2009). Eﬀective strategies for management of hypertension after
vascular endothelial growth factor signaling inhibition therapy: Results from a phase
II randomized, factorial, double-blind study of cediranib in patients with advanced
solid tumors. Journal of Clinical Oncology, 27, 6152–6159.
Lankhorst, S., Kappers, M. H. W., van Esch, J. H. M., Danser, A. H. J., & van den
Meiracker, A. H. (2013). Mechanism of hypertension and proteinuria during angio-
genesis inhibition: Evolving role of endothelin-1. Journal of Hypertension, 31,
444–454.
Lankhorst, S., Kappers, M. H. W., van Esch, J. H. M., Danser, A. H. J., & van den
Meiracker, A. H. (2014). Hypertension during vascular endothelial growth factor
inhibition: Focus on nitric oxide, endothelin-1, and oxidative stress.
Antioxidants & Redox Signaling, 20, 135–145.
Lee, S., Chen, T. T., Barber, C. L., Jordan, M. C., Murdock, J., Desai, S., et al. (2007).
Autocrine VEGF signaling is required for vascular homeostasis. Cell, 130, 691–703.
Levy, D., Ehret, G. B., Rice, K., Verwoert, G. C., Launer, L. J., Dehghan, A., et al. (2009).
Genome-wide association study of blood pressure and hypertension. Nature Genetics,
41, 677–687.
Levy, D., Larson, M. G., Benjamin, E. J., Newton-Cheh, C., Wang, T. J., Hwang, S.-J., et al.
(2007). Framingham Heart Study 100K Project: Genome-wide associations for blood
pressure and arterial stiﬀness. BMC Medical Genetics, 8, S3.
Li, B., Ogasawara, A. K., Yang, R., Wei, W., He, G. W., Zioncheck, T. F., et al. (2002). KDR
(VEGF receptor 2) is the major mediator for the hypotensive eﬀect of VEGF.
Hypertension, 39, 1095–1100.
Liu, C., Kraja, A. T., Smith, J. A., Brody, J. A., Franceschini, N., Bis, J. C., et al. (2016).
Meta-analysis identiﬁes common and rare variants inﬂuencing blood pressure and
overlapping with metabolic trait loci. Nature Genetics, 48, 1162–1170.
Liu, S., Premont, R. T., Kontos, C. D., Huang, J., & Rockey, D. C. (2003). Endothelin-1
activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein beta-
gamma subunit signaling to protein kinase B/Akt. Journal of Biological Chemistry, 278,
49929–49935.
Loupakis, F., Bria, E., Vaccaro, V., Cuppone, F., Milella, M., Carlini, P., et al. (2010).
Magnitude of beneﬁt of the addition of bevacizumab to ﬁrst-line chemotherapy for
metastatic colorectal cancer: Meta-analysis of randomized clinical trials. Journal of
Experimental & Clinical Cancer Research, 29, 58.
Lu, J.-F., Bruno, R., Eppler, S., Novotny, W., Lum, B., & Gaudreault, J. (2008). Clinical
pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemotherapy
and Pharmacology, 62, 779–786.
Maitland, M. L., Bakris, G. L., Black, H. R., Chen, H. X., Durand, J. B., Elliott, W. J., et al.
(2010). Initial assessment, surveillance, and management of blood pressure in pa-
tients receiving vascular endothelial growth factor signaling pathway inhibitors.
Journal of the National Cancer Institute, 102, 596–604.
Maitland, M. L., Moshier, K., Imperial, J., Kasza, K. E., Karrison, T., Elliott, W., et al.
(2006). Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the
vascular endothelial growth factor (VEGF) signaling pathway. Journal of Clinical
Oncology (Meeting Abstracts), 24, 2035.
Maitland, M. L., Xu, C. F., Cheng, Y. C., Kistner-Griﬃn, E., Ryan, K. A., Karrison, T. G.,
et al. (2015). Identiﬁcation of a variant in KDR associated with serum VEGFR2 and
pharmacodynamics of pazopanib. Clinical Cancer Research, 21, 365–372.
Mangoni, A. A., Woodman, R. J., Kichenadasse, G., Rowland, A., & Sorich, M. J. (2016).
Anti-VEGF-induced hypertension and cancer outcomes: Translating research into
clinical practice. Expert Review of Precision Medicine and Drug Development, 1,
125–127.
Matsuura, A., Yamochi, W., Hirata, K. I., Kawashima, S., & Yokoyama, M. (1998).
Stimulatory interaction between vascular endothelial growth factor and endothelin-1
on each gene expression. Hypertension, 32, 89–95.
Miall, W. E., & Oldham, P. D. (1963). The hereditary factor in arterial blood-pressure.
British Medical Journal, 1, 75–80.
Mir, O., Coriat, R., Cabanes, L., Ropert, S., Billemont, B., Alexandre, J., et al. (2011). An
observational study of bevacizumab-induced hypertension as a clinical biomarker of
antitumor activity. The Oncologist, 16, 1325–1332.
Morita, S., Uehara, K., Nakayama, G., Shibata, T., Oguri, T., Inada-Inoue, M., et al. (2013).
Association between bevacizumab-related hypertension and vascular endothelial
growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic
colorectal cancer. Cancer Chemotherapy and Pharmacology, 71, 405–411.
M. Li, D.L. Kroetz Pharmacology and Therapeutics 182 (2018) 152–160
159
Morrison, A. C., Bis, J. C., Hwang, S.-J., Ehret, G. B., Lumley, T., Rice, K., et al. (2014).
Sequence analysis of six blood pressure candidate regions in 4,178 individuals: The
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) targeted
sequencing study. PloS One, 9, e109155.
Mourad, J. J., des Guetz, G., Debbabi, H., & Levy, B. I. (2008). Blood pressure rise fol-
lowing angiogenesis inhibition by bevacizumab: A crucial role for microcirculation.
Annals of Oncology, 19, 927–934.
Munroe, P. B., Barnes, M. R., & Caulﬁeld, M. J. (2013). Advances in blood pressure
genomics. Circulation Research, 112, 1365–1379.
National Cancer Institute (2010). Common Terminology Criteria for Adverse Events.
Retrieved from http://ctep.cancer.gov/reporting/ctc.html, v4.03.
Neagoe, P.-E., Lemieux, C., & Sirois, M. G. (2005). Vascular endothelial growth factor
(VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF re-
ceptor-1 and -2 heterodimer. Journal of Biological Chemistry, 280, 9904–9912.
Newton-Cheh, C., Johnson, T., Gateva, V., Tobin, M. D., Bochud, M., Coin, L., et al.
(2009). Genome-wide association study identiﬁes eight loci associated with blood
pressure. Nature Genetics, 41, 666–676.
Oparil, S., Zaman, M. A., & Calhoun, D. A. (2003). Pathogenesis of hypertension. Annals of
Internal Medicine, 139, 761–776.
Ozcan, C., Wong, S. J., & Hari, P. (2006). Reversible posterior leukoencephalopathy
syndrome and bevacizumab. The New England Journal of Medicine, 354, 980–982.
Padmanabhan, S., Caulﬁeld, M., & Dominiczak, A. F. (2015). Genetic and molecular as-
pects of hypertension. Circulation Research, 116, 937–959.
Panoilia, E., Schindler, E., Samantas, E., Aravantinos, G., Kalofonos, H. P., Christodoulou,
C., et al. (2015). A pharmacokinetic binding model for bevacizumab and VEGF165 in
colorectal cancer patients. Cancer Chemotherapy and Pharmacology, 75, 791–803.
Ranpura, V., Pulipati, B., Chu, D., Zhu, X., & Wu, S. (2010). Increased risk of high-grade
hypertension with bevacizumab in cancer patients: A meta-analysis. American Journal
of Hypertension, 23, 460–468.
Renner, W., Kotschan, S., Hoﬀmann, C., Obermayer-Pietsch, B., & Pilger, E. (2000). A
common 936 C/T mutation in the gene for vascular endothelial growth factor is as-
sociated with vascular endothelial growth factor plasma levels. Journal of Vascular
Research, 37, 443–448.
Rimoldi, S. F., Scherrer, U., & Messerli, F. H. (2014). Secondary arterial hypertension:
When, who, and how to screen? European Heart Journal, 35, 1245–1254.
Robinson, E. S., Khankin, E. V., Karumanchi, S. A., & Humphreys, B. D. (2010).
Hypertension induced by vascular endothelial growth factor signaling pathway in-
hibition: Mechanisms and potential use as a biomarker. Seminars in Nephrology, 30,
591–601.
Safar, M. E., Levy, B. I., & Struijker-Boudier, H. (2003). Current perspectives on arterial
stiﬀness and pulse pressure in hypertension and cardiovascular diseases. Circulation,
107, 2864–2869.
Sarabipour, S., Ballmer-Hofer, K., & Hristova, K. (2016). VEGFR-2 conformational switch
in response to ligand binding. eLife, 5, e13876.
Schneider, B. P., Li, L., Shen, F., Miller, K. D., Radovich, M., O'Neill, A., et al. (2014).
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and
ECOG-2100. British Journal of Cancer, 111, 1241–1248.
Schneider, B. P., Wang, M., Radovich, M., Sledge, G. W., Badve, S., Thor, A., et al. (2008).
Association of vascular endothelial growth factor and vascular endothelial growth
factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel com-
pared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
Journal of Clinical Oncology, 26, 4672–4678.
Schulz, E., Jansen, T., Wenzel, P., Daiber, A., & Münzel, T. (2008). Nitric oxide, tetra-
hydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension.
Antioxidants & Redox Signaling, 10, 1115–1126.
Seet, R. C. S., & Rabinstein, A. A. (2012). Clinical features and outcomes of posterior
reversible encephalopathy syndrome following bevacizumab treatment. QJM: An
International Journal of Medicine, 105, 69–75.
Semeniuk-Wojtaś, A., Lubas, A., Stec, R., Szczylik, C., & Niemczyk, S. (2016). Inﬂuence of
tyrosine kinase inhibitors on hypertension and nephrotoxicity in metastatic renal cell
cancer patients. International Journal of Molecular Sciences, 17, 2073.
Seol, H.-J., Oh, M.-J., & Kim, H.-J. (2011). Endothelin-1 expression by vascular en-
dothelial growth factor in human umbilical vein endothelial cells and aortic smooth
muscle cells. Hypertension in Pregnancy, 30, 295–301.
Sibertin-Blanc, C., Mancini, J., Fabre, A., Lagarde, A., Del Grande, J., Levy, N., et al.
(2015). Vascular Endothelial Growth Factor A c.*237C > T polymorphism is asso-
ciated with bevacizumab eﬃcacy and related hypertension in metastatic colorectal
cancer. Digestive and Liver Disease, 47, 331–337.
Slusarz, K. M., Merker, V. L., Muzikansky, A., Francis, S. A., & Plotkin, S. R. (2014). Long-
term toxicity of bevacizumab therapy in neuroﬁbromatosis 2 patients. Cancer
Chemotherapy and Pharmacology, 73, 1197–1204.
Snieder, H., Hayward, C. S., Perks, U., Kelly, R. P., Kelly, P. J., & Spector, T. D. (2000).
Heritability of central systolic pressure augmentation: A twin study. Hypertension, 35,
574–579.
Star, G. P., Giovinazzo, M., Lamoureux, E., & Langleben, D. (2014). Eﬀects of vascular
endothelial growth factor on endothelin-1 production by human lung microvascular
endothelial cells in vitro. Life Sciences, 118, 191–194.
Steﬀensen, K. D., Waldstrøm, M., Brandslund, I., & Jakobsen, A. (2010). The relationship
of VEGF polymorphisms with serum VEGF levels and progression-free survival in
patients with epithelial ovarian cancer. Gynecologic Oncology, 117, 109–116.
Su, E.-N., Cringle, S. J., McAllister, I. L., & Yu, D.-Y. (2012). An experimental study of
VEGF induced changes in vasoactivity in pig retinal arterioles and the inﬂuence of an
anti-VEGF agent. BMC Ophthalmology, 12, 10.
Surendran, P., Drenos, F., Young, R., Warren, H., Cook, J. P., Manning, A. K., et al. (2016).
Trans-ancestry meta-analyses identify rare and common variants associated with
blood pressure and hypertension. Nature Genetics, 48, 1151–1161.
Tao, Q., Backer, M. V., Backer, J. M., & Terman, B. I. (2001). Kinase insert domain re-
ceptor (KDR) extracellular immunoglobulin-like domains 4-7 contain structural fea-
tures that block receptor dimerization and vascular endothelial growth factor-in-
duced signaling. Journal of Biological Chemistry, 276, 21916–21923.
The International Consortium for Blood Pressure Genome-Wide Association Studies
(2011). Genetic variants in novel pathways inﬂuence blood pressure and cardiovas-
cular disease risk. Nature, 478, 103–109.
Thijs, A. M. J., van Herpen, C. M. L., Sweep, F. C. G. J., Geurts-Moespot, A., Smits, P., van
der Graaf, W. T. A., & Rongen, G. A. (2013). Role of endogenous vascular endothelial
growth factor in endothelium-dependent vasodilation in humans. Hypertension, 61,
1060–1065.
van Erp, N. P., Eechoute, K., van der Veldt, A. A., Haanen, J. B., Reyners, A. K. L.,
Mathijssen, R. H. J., et al. (2009). Pharmacogenetic pathway analysis for determi-
nation of sunitinib-induced toxicity. Journal of Clinical Oncology, 27, 4406–4412.
Veronese, M. L., Mosenkis, A., Flaherty, K. T., Gallagher, M., Stevenson, J. P., Townsend,
R. R., & O'Dwyer, P. J. (2006). Mechanisms of hypertension associated with BAY 43-
9006. Journal of Clinical Oncology, 24, 1363–1369.
Vignon-Zellweger, N., Heiden, S., Miyauchi, T., & Emoto, N. (2012). Endothelin and
endothelin receptors in the renal and cardiovascular systems. Life Sciences, 91,
490–500.
Wain, L. V., Verwoert, G. C., O'Reilly, P. F., Shi, G., Johnson, T., Johnson, A. D., et al.
(2011). Genome-wide association study identiﬁes six new loci inﬂuencing pulse
pressure and mean arterial pressure. Nature Genetics, 43, 1005–1011.
Wang, Y., Fei, D., Vanderlaan, M., & Song, A. (2004). Biological activity of bevacizumab,
a humanized anti-VEGF antibody in vitro. Angiogenesis, 7, 335–345.
Wang, N.-Y., Young, J. H., Meoni, L. A., Ford, D. E., Erlinger, T. P., & Klag, M. J. (2008).
Blood pressure change and risk of hypertension associated with parental hyperten-
sion: the Johns Hopkins Precursors Study. Archives of Internal Medicine, 168, 643–648.
Wang, Y., Zheng, Y., Zhang, W., Yu, H., Lou, K., Zhang, Y., et al. (2007). Polymorphisms
of KDR gene are associated with coronary heart disease. Journal of the American
College of Cardiology, 50, 760–767.
Warren, H. R., Evangelou, E., Cabrera, C. P., Gao, H., Ren, M., Mifsud, B., et al. (2017).
Genome-wide association analysis identiﬁes novel blood pressure loci and oﬀers
biological insights into cardiovascular risk. Nature Genetics, 49, 403–415.
Wheeler-Jones, C., Abu-Ghazaleh, R., Cospedal, R., Houliston, R. A., Martin, J., &
Zachary, I. (1997). Vascular endothelial growth factor stimulates prostacyclin pro-
duction and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44
mitogen-activated protein kinase. FEBS Letters, 420, 28–32.
Wicki, A., Hermann, F., Prêtre, V., Winterhalder, R., Kueng, M., von Moos, R., et al.
(2014). Pre-existing antihypertensive treatment predicts early increase in blood
pressure during bevacizumab therapy: The prospective AVALUE cohort study.
Oncology Research and Treatment, 37, 230–236.
World Health Organization (2013). A global brief on hypertension: Silent killer, global
public health crisis. Retrieved from http://ish-world.com/downloads/pdf/global_
brief_hypertension.pdf.
Yu, B., Pulit, S. L., Hwang, S.-J., Brody, J. A., Amin, N., Auer, P. L., et al. (2016). Rare
exome sequence variants in CLCN6 reduce blood pressure levels and hypertension
risk. Circulation: Cardiovascular Genetics, 9, 64–70.
Zand, R., Kazemi, S., Barr, J., & Afshani, M. (2012). Subarachnoid hemorrhage with se-
vere vasospasm after bevacizumab therapy: A case report. Neurology, 78, P02.205.
Zhu, X., Wu, S., Dahut, W. L., & Parikh, C. R. (2007). Risks of proteinuria and hy-
pertension with bevacizumab, an antibody against vascular endothelial growth
factor: Systematic review and meta-analysis. American Journal of Kidney Diseases, 49,
186–193.
Zou, A.-P., & Cowley, A. W. (1999). Role of nitric oxide in the control of renal function
and salt sensitivity. Current Hypertension Reports, 1, 178–186.
M. Li, D.L. Kroetz Pharmacology and Therapeutics 182 (2018) 152–160
160
